Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

van der Heijde, D, Durez, P, Schett, G, Naredo, E, Østergaard, M, Meszaros, G, De Leonardis, F, de la Torre, I, López-Romero, P, Schlichting, D, Nantz, E & Fleischmann, R 2018, 'Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study' Clinical Rheumatology, bind 37, nr. 9, s. 2381-2390. https://doi.org/10.1007/s10067-018-4221-0

APA

CBE

MLA

Vancouver

Author

van der Heijde, Désirée ; Durez, Patrick ; Schett, Georg ; Naredo, Esperanza ; Østergaard, Mikkel ; Meszaros, Gabriella ; De Leonardis, Francesco ; de la Torre, Inmaculada ; López-Romero, Pedro ; Schlichting, Douglas ; Nantz, Eric ; Fleischmann, Roy. / Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study. I: Clinical Rheumatology. 2018 ; Bind 37, Nr. 9. s. 2381-2390.

Bibtex

@article{f501b3f34bc04d299d0b1b0a5cd2ee52,
title = "Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study",
abstract = "The objective of this study was to evaluate structural damage progression based on clinical response in rheumatoid arthritis patients with no or limited prior disease-modifying anti-rheumatic drug treatment receiving the Janus kinase (JAK)1/JAK2 inhibitor baricitinib 4 mg, methotrexate (MTX), or the combination. Data from the phase 3 RA-BEGIN study were analysed post hoc. Proportions of patients with structural damage progression (change from baseline greater than the smallest detectable change in modified total Sharp score) at week 52 were evaluated based on sustained Disease Activity Score for 28-joint count with serum high-sensitivity C-reactive protein (DAS28-hsCRP) ≤ 3.2 or Simplified Disease Activity Index (SDAI) score ≤ 11; no formal statistical comparisons between treatments were performed to test these proportions. Baseline factors associated with risk of structural damage progression, including Clinical Disease Activity Index (CDAI) score, were identified using multivariate analysis. Patients achieving versus not achieving sustained DAS28-hsCRP ≤ 3.2 or SDAI score ≤ 11 were less likely to experience structural damage progression at week 52. In patients achieving these responses, structural damage progression was less likely with baricitinib monotherapy or plus MTX than with MTX monotherapy. In patients not achieving these sustained clinical thresholds, structural damage progression was less likely with baricitinib plus MTX than with either monotherapy. Independent of treatment, baseline factors significantly associated with increased risk of structural damage progression included higher hsCRP and CDAI score, smoking, female sex, and lower body mass index. In conclusion, patients achieving versus not achieving sustained DAS28-hsCRP ≤ 3.2 or SDAI score ≤ 11 were less likely to show structural damage progression, irrespective of treatment.",
author = "{van der Heijde}, D{\'e}sir{\'e}e and Patrick Durez and Georg Schett and Esperanza Naredo and Mikkel {\O}stergaard and Gabriella Meszaros and {De Leonardis}, Francesco and {de la Torre}, Inmaculada and Pedro L{\'o}pez-Romero and Douglas Schlichting and Eric Nantz and Roy Fleischmann",
note = "COPECARE",
year = "2018",
month = "9",
doi = "10.1007/s10067-018-4221-0",
language = "English",
volume = "37",
pages = "2381--2390",
journal = "Clinical Rheumatology",
issn = "0770-3198",
publisher = "Springer U K",
number = "9",

}

RIS

TY - JOUR

T1 - Structural damage progression in patients with early rheumatoid arthritis treated with methotrexate, baricitinib, or baricitinib plus methotrexate based on clinical response in the phase 3 RA-BEGIN study

AU - van der Heijde, Désirée

AU - Durez, Patrick

AU - Schett, Georg

AU - Naredo, Esperanza

AU - Østergaard, Mikkel

AU - Meszaros, Gabriella

AU - De Leonardis, Francesco

AU - de la Torre, Inmaculada

AU - López-Romero, Pedro

AU - Schlichting, Douglas

AU - Nantz, Eric

AU - Fleischmann, Roy

N1 - COPECARE

PY - 2018/9

Y1 - 2018/9

N2 - The objective of this study was to evaluate structural damage progression based on clinical response in rheumatoid arthritis patients with no or limited prior disease-modifying anti-rheumatic drug treatment receiving the Janus kinase (JAK)1/JAK2 inhibitor baricitinib 4 mg, methotrexate (MTX), or the combination. Data from the phase 3 RA-BEGIN study were analysed post hoc. Proportions of patients with structural damage progression (change from baseline greater than the smallest detectable change in modified total Sharp score) at week 52 were evaluated based on sustained Disease Activity Score for 28-joint count with serum high-sensitivity C-reactive protein (DAS28-hsCRP) ≤ 3.2 or Simplified Disease Activity Index (SDAI) score ≤ 11; no formal statistical comparisons between treatments were performed to test these proportions. Baseline factors associated with risk of structural damage progression, including Clinical Disease Activity Index (CDAI) score, were identified using multivariate analysis. Patients achieving versus not achieving sustained DAS28-hsCRP ≤ 3.2 or SDAI score ≤ 11 were less likely to experience structural damage progression at week 52. In patients achieving these responses, structural damage progression was less likely with baricitinib monotherapy or plus MTX than with MTX monotherapy. In patients not achieving these sustained clinical thresholds, structural damage progression was less likely with baricitinib plus MTX than with either monotherapy. Independent of treatment, baseline factors significantly associated with increased risk of structural damage progression included higher hsCRP and CDAI score, smoking, female sex, and lower body mass index. In conclusion, patients achieving versus not achieving sustained DAS28-hsCRP ≤ 3.2 or SDAI score ≤ 11 were less likely to show structural damage progression, irrespective of treatment.

AB - The objective of this study was to evaluate structural damage progression based on clinical response in rheumatoid arthritis patients with no or limited prior disease-modifying anti-rheumatic drug treatment receiving the Janus kinase (JAK)1/JAK2 inhibitor baricitinib 4 mg, methotrexate (MTX), or the combination. Data from the phase 3 RA-BEGIN study were analysed post hoc. Proportions of patients with structural damage progression (change from baseline greater than the smallest detectable change in modified total Sharp score) at week 52 were evaluated based on sustained Disease Activity Score for 28-joint count with serum high-sensitivity C-reactive protein (DAS28-hsCRP) ≤ 3.2 or Simplified Disease Activity Index (SDAI) score ≤ 11; no formal statistical comparisons between treatments were performed to test these proportions. Baseline factors associated with risk of structural damage progression, including Clinical Disease Activity Index (CDAI) score, were identified using multivariate analysis. Patients achieving versus not achieving sustained DAS28-hsCRP ≤ 3.2 or SDAI score ≤ 11 were less likely to experience structural damage progression at week 52. In patients achieving these responses, structural damage progression was less likely with baricitinib monotherapy or plus MTX than with MTX monotherapy. In patients not achieving these sustained clinical thresholds, structural damage progression was less likely with baricitinib plus MTX than with either monotherapy. Independent of treatment, baseline factors significantly associated with increased risk of structural damage progression included higher hsCRP and CDAI score, smoking, female sex, and lower body mass index. In conclusion, patients achieving versus not achieving sustained DAS28-hsCRP ≤ 3.2 or SDAI score ≤ 11 were less likely to show structural damage progression, irrespective of treatment.

U2 - 10.1007/s10067-018-4221-0

DO - 10.1007/s10067-018-4221-0

M3 - Journal article

VL - 37

SP - 2381

EP - 2390

JO - Clinical Rheumatology

JF - Clinical Rheumatology

SN - 0770-3198

IS - 9

ER -

ID: 56068834